Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Guy Rozen

Cardiovascular Disease Melrose, MA Medical Doctor

NPI 1871903377 CMS profile 388153

50 Rowe St Ste 500, Melrose, MA 02176

Open in the dashboard

General payments

$55,110

379 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Guy Rozen of Melrose, MA is reported in the CMS Open Payments database as having received $55,110 across 379 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,100 123
2024 General $23,145 135
2023 General $13,042 87
2022 General $2,823 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Guy Rozen
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Guy Rozen were reported at $16,100. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Guy Rozen Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $2,823 $395 $121–$1,211 $149
2023 $13,042 $443 $136–$1,283 $160
2024 $23,145 $450 $136–$1,323 $164
2025 $16,100 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Abbott Laboratories $35,664 213 payments
  2. Biosense Webster, Inc. $11,262 76 payments
  3. Medtronic, Inc. $2,989 35 payments
  4. Boston Scientific Corporation $2,910 24 payments
  5. Biotronik Inc. $1,627 15 payments
  6. Impulse Dynamics (USA) Inc. $272 3 payments
  7. Cardiva Medical, Inc. $200 8 payments
  8. Pfizer Inc. $106 3 payments
  9. Philips Electronics North America Corporation $55 1 payment
  10. Cordis US Corp. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $25,932 51 payments
  2. Food and Beverage $19,528 324 payments
  3. Consulting Fee $5,400 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,250 3 payments
Products named General payments · program years 2022–2025
  1. ENSITE $15,559 22 payments
  2. Carto 3 $10,171 52 payments
  3. ENSITE PRECISION $6,393 22 payments
  4. AMPLATZER AMULET $4,262 41 payments
  5. AVEIR Cardiac Rhythm Management $2,208 29 payments
  6. AVEIR Cardiac Rhythm Management $1,111 11 payments
  7. AVEIR Cardiac Rhythm Management $928 15 payments
  8. PROCLAIM $909 2 payments
  9. GALLANT $806 13 payments
  10. JOT DX $510 11 payments
  11. Other $8,745 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

179

Median for Cardiology: 2,533

Drug cost

$47,779

Median for Cardiology: $485,213

Branded share of claims

27.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 50 $45,045
Flecainide Acetate Generic 24 $1,136
Amiodarone Hcl Generic 76 $1,040
Metoprolol Succinate Generic 29 $557

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$184,321

Medicare's payments for the services billed

Medicare patients

884

Average age 74

Services billed

1,839

351 women, 533 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 63%
Ischemic heart disease 56%
Heart failure 51%
Arthritis 47%
Chronic kidney disease 43%
Diabetes 37%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

379 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record